Wall Street Zen Upgrades Hillstream Biopharma (NASDAQ:CNTN) to Hold

Hillstream Biopharma (NASDAQ:CNTN) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings cut shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Hillstream Biopharma Price Performance

Shares of CNTN stock opened at $2.19 on Friday. Hillstream Biopharma has a fifty-two week low of $1.75 and a fifty-two week high of $9.08. The company has a fifty day moving average price of $2.39. The stock has a market cap of $174.50 million, a price-to-earnings ratio of -4.38 and a beta of 1.45.

Insider Activity

In related news, Director Gary S. Stetz sold 12,500 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $3.47, for a total value of $43,375.00. Following the completion of the sale, the director owned 134,175 shares of the company’s stock, valued at approximately $465,587.25. This trade represents a 8.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.34% of the stock is owned by company insiders.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.